@article{article, title  = {{Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis}},

 publisher = {{National Society for Cutaneous Medicine}},

 url = {{}},

 year = {{2020}},

 month = {{10}},

 author = {{Cork M and Thaçi D and Eichenfield L and Arkwright P and Chen Z and Kamal M and O'Malley J and Bansal A}},

 doi = {{10.25251/skin.4.supp.104}},

 volume = {{4}},

 journal = {{SKIN The Journal of Cutaneous Medicine}},

 issue = {{6}},

 pages = {{s104-s104}},

 note = {{Accessed on 2024/12/22}}}